ArticleArthritis care & research2017
Perioperative Timing of Infliximab and the Risk of Serious Infection After Elective Hip and Knee Arthroplasty.
Article in Arthritis care & research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 78 citations in OpenAlex.
- Perioperative Management of Antirheumatic Medications in Adults with Rheumatoid Arthritis Undergoing Arthroplasty and Other Orthopedic Procedures: A Systematic Review.Medicina (Kaunas, Lithuania) · 2026Pooled it
- Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease.The Cochrane database of systematic reviews · 2020Pooled it
- Review
- The impact of noninfective enteritis and colitis on outcomes following shoulder arthroplasty: a propensity-matched retrospective cohort study of 8,574 patients.JSES international · 2026Article
- Does perioperative discontinuation of anti-rheumatic drugs increase postoperative complications in orthopedic surgery for rheumatoid arthritis?Arthritis research & therapy · 2025Article
- Risk factors for treatment failure in late acute periprosthetic joint infection in patients with rheumatoid arthritis treated with surgical debridement - a case-control study.Journal of bone and joint infection · 2025Article
- Is Total Joint Arthroplasty an Effective and Safe Option for Psoriatic Arthritis Patients? A Scoping Review.Journal of clinical medicine · 2024Article
- A Meta-Analysis Examining the Effect of Perioperative Biologic Disease-Modifying Anti-Rheumatic Medications on Postoperative Wound Complications in Various Orthopedic Surgeries.Journal of clinical medicine · 2024Review
- Perioperative immunosuppressive therapy and coronary ostial angioplasty for unstable angina with Takayasu arteritis.Journal of cardiology cases · 2023Article
- Australian recommendations on perioperative use of disease-modifying anti-rheumatic drugs in people with inflammatory arthritis undergoing elective surgery.Internal medicine journal · 2023Article
- [Perioperative management of treatment of patients with inflammatory rheumatic diseases : Updated recommendations of the German Society of Rheumatology].Zeitschrift fur Rheumatologie · 2022Article
- Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management.Psoriasis (Auckland, N.Z.) · 2022Review
- Safety of fluoroscopically guided pain procedures in patients receiving cytotoxic chemotherapy: a retrospective analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Article
- Pre-operative withholding of infliximab and the risk of infections after major surgery in patients with rheumatoid arthritis.Rheumatology (Oxford, England) · 2020Article
- Total Knee Periprosthetic Joint Infection in the Setting of Hematologic Malignancy: Considerations for Management.Arthroplasty today · 2020Article
- Rheumatoid Arthritis Flares After Total Hip and Total Knee Arthroplasty: Outcomes at One Year.Arthritis care & research · 2020Observational
- Review
- Immunosuppression and the risk of readmission and mortality in patients with rheumatoid arthritis undergoing hip fracture, abdominopelvic and cardiac surgery.Annals of the rheumatic diseases · 2020Article
- Active ankylosing spondylitis increases blood loss during total hip arthroplasty for a stiff hip joint.BMC musculoskeletal disorders · 2020Article
- Incidence of Serious Infections and Design of Utilization and Safety Studies for Biologic and Biosimilar Surveillance.Journal of managed care & specialty pharmacy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
objectiveThe optimal timing of tumor necrosis factor antagonists before elective surgery is unknown. This study evaluated the association between infliximab timing and serious infection after elective hip or knee arthroplasty.
methodsA retrospective cohort study evaluated US Medicare patients with rheumatoid arthritis, inflammatory bowel disease, psoriasis, psoriatic arthritis, or ankylosing spondylitis who received infliximab within 6 months of elective knee or hip arthroplasty from 2007 to 2013. Propensity-adjusted analyses examined whether infliximab stop timing (time between the most recent infusion and surgery) was associated with hospitalized infection within 30 days or prosthetic joint infection (PJI) within 1 year.
resultsHospitalized infection within 30 days occurred after 270 of 4,288 surgeries (6.3%). Infliximab stop timing <4 weeks versus 8-12 weeks was not associated with an increase in infection within 30 days (propensity-adjusted odds ratio [OR] 0.90 [95% confidence interval (95% CI) 0.60-1.34]). The rate of PJI was 2.9 per 100 person-years and was not increased in patients with stop timing <4 weeks versus 8-12 weeks (hazard ratio [HR] 0.98 [95% CI 0.52-1.87]). Glucocorticoid dosage >10 mg/day was associated with increased risk of 30-day infection (OR 2.11 [95% CI 1.30-3.40]) and PJI (HR 2.70 [95% CI 1.30-5.60]). Other risk factors for infection included elderly age, comorbidities, revision surgery, and previous hospitalized infection.
conclusionAdministering infliximab within 4 weeks of elective knee or hip arthroplasty was not associated with a higher risk of short- or long-term serious infection compared to withholding infliximab for longer time periods. Glucocorticoid use, especially >10 mg/day, was associated with an increased infection risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.